Eflornithine for neuroblastoma: EMA approval timelines and how to avoid ...
Iwilfin (eflornithine), recently FDA-approved, reduces relapse risk in high-risk neuroblastoma patients. Its EMA approval is pending, with potential availability in Europe by mid-2025. Patients can access it via clinical trials or Named Patient Import before official approval.
Related Clinical Trials
Reference News
Eflornithine (Iwilfin) was FDA-approved on December 13, 2023, for high-risk neuroblastoma patients post-therapy response. It's the first therapy aimed at reducing relapse risk in pediatric patients. Dosage varies by body surface area, with warnings for serious side effects like myelosuppression and hepatotoxicity.
Iwilfin (eflornithine), recently FDA-approved, reduces relapse risk in high-risk neuroblastoma patients. Its EMA approval is pending, with potential availability in Europe by mid-2025. Patients can access it via clinical trials or Named Patient Import before official approval.